Results 211 to 220 of about 56,672 (288)

The clinical use of cryoprecipitate and fibrinogen concentrate: A scoping review

open access: yesTransfusion, EarlyView.
Abstract Background Acquired hypofibrinogenemia poses significant bleeding risks. Concentrated sources of fibrinogen, whether cryoprecipitate or fibrinogen concentrates, are widely used. This scoping review aimed to identify and map the available evidence on fibrinogen supplementation.
Aaron S. Hess   +15 more
wiley   +1 more source

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

open access: yes
Transfusion, EarlyView.
Thane Kubik   +2 more
wiley   +1 more source

Assessment of the efficacy of large volume delayed sampling primary culture and pathogen reduction in preventing septic reactions from platelet transfusions

open access: yesTransfusion, EarlyView.
Abstract Background Many mitigation processes have been introduced to reduce septic transfusion reactions (STRs) caused by the transfusion of bacterially contaminated PLTs. Methods The efficacy of primary culture and pathogen reduction is assessed in this review using data from long‐term hemovigilance programs in the US, Canada, UK, France, Switzerland,
Michael R. Jacobs
wiley   +1 more source

Direct and indirect medical costs associated with transfusion-dependent beta-thalassemia in Brazil, Thailand, and India. [PDF]

open access: yesTher Adv Hematol
Seth T   +14 more
europepmc   +1 more source

Parenteral iron—Does it increase infection risk?

open access: yesVox Sanguinis, EarlyView.
Abstract Background and Objectives Iron deficiency (ID) and iron deficiency anaemia (IDA) are prevalent conditions impacting various patient populations, both surgical and non‐surgical conditions. The advent of patient blood management (PBM) has promoted intravenous (IV) iron therapy as an alternative to oral iron and blood transfusions.
Joyisa Deb   +7 more
wiley   +1 more source

The need for dried plasma—Still a national issue: Where are we and recommendations

open access: yes
Transfusion, EarlyView.
Anthony E. Pusateri   +24 more
wiley   +1 more source

Protection of fundamental human rights by improving patient access to plasma‐derived therapies and donor health protection

open access: yesVox Sanguinis, EarlyView.
Abstract Background and Objectives The main use of plasma has evolved into market‐driven plasma‐derived medicinal products (PDMPs), but it still requires donors. Availability of PDMPs in access to care is often considered restrictively, in terms of volumes of plasma required for production and whether or not to remunerate donors.
Jean‐Baptiste Thibert   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy